Elimination of porcine hemopoietic cells by macrophages in mice.
The difficulty in achieving donor hemopoietic engraftment across highly disparate xenogeneic species barriers poses a major obstacle to exploring xenograft tolerance induction by mixed chimerism. In this study, we observed that macrophages mediate strong rejection of porcine hemopoietic cells in mice. Depletion of macrophages with medronate-encapsulated liposomes (M-liposomes) markedly improved porcine chimerism, and early chimerism in particular, in sublethally irradiated immunodeficient and lethally irradiated immunocompetent mice. Although porcine chimerism in the peripheral blood and spleen of M-liposome-treated mice rapidly declined after macrophages had recovered and became indistinguishable from controls by wk 5 post-transplant, the levels of chimerism in the marrow of these mice remained higher than those in control recipients at 8 wks after transplant. These results suggest that macrophages that developed in the presence of porcine chimerism were not adapted to the porcine donor and that marrow-resident macrophages did not phagocytose porcine cells. Moreover, M-liposome treatment had no effect on the survival of porcine PBMC injected into the recipient peritoneal cavity, but was essential for the migration and relocation of these cells into other tissues/organs, such as spleen, bone marrow, and peripheral blood. Together, our results suggest that murine reticuloendothelial macrophages, but not those in the bone marrow and peritoneal cavity, play a significant role in the clearance of porcine hemopoietic cells in vivo. Because injection of M-liposomes i.v. mainly depletes splenic macrophages and liver Kupffer cells, the spleen and/or liver are likely the primary sites of porcine cell clearance in vivo.
Abe
Masahiro
M
Bone Marrow Transplantation Section, Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02129, USA.
Cheng
Jane
J
Qi
Jin
J
Glaser
Roseann M
RM
Thall
Aron D
AD
Sykes
Megan
M
Yang
Yong-Guang
YG
D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000379:methods / Q000401:mortality; D002465:Cell Movement / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D004164:Diphosphonates / Q000008:administration & dosage; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008081:Liposomes / Q000008:administration & dosage; D008264:Macrophages / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D008822:Mice, Transgenic; D009928:Organ Specificity / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D010529:Peritoneal Cavity / Q000166:cytology; D011828:Radiation Chimera / Q000235:genetics / Q000276:immunology*; D013552:Swine; D013556:Swine, Miniature / Q000235:genetics / Q000276:immunology*; D019172:Transplantation Conditioning / Q000379:methods; D014183:Transplantation, Heterologous / Q000276:immunology* / Q000379:methods / Q000401:mortality
D004164:Diphosphonates; D008081:Liposomes